KEI Recommendations on the work of the SCCR on a treaty for broadcasting organizations

KEI Recommendations on the work of the SCCR on a treaty for broadcasting organizations
Prepared for WIPO General Assembly
October 4, 2017

KEI recommends taking the broadcasting treaty off the agenda of the SCCR, until (1) the proponents of the treaty can explain what they expect the treaty will do, in practical terms, (2) how the treaty will impact copyright owners and persons who want access to information distributed by broadcasters, and (3) if there is a realistic expectation of agreement on the substance of the treaty.

Continue Reading

Uncategorized

KEI asks HHS to use Bayh-Dole rights in Zinbryta patent (drug for multiple sclerosis)

Attached is a letter sent on September 14, 2017 to Andrew Bremberg, an Assistant to the President and the Director of the Domestic Policy Council at the White House, and Keagan Lenihan, a Senior Adviser to HHS Secretary Tom Price, regarding Zinbrytra (INN: daclizumab), a drug to approved by the FDA to treat multiple sclerosis. (PDF version here)

Continue Reading

Florida members in House and Senate Object to Proposed Exclusive License of Zika Vaccine

Yesterday, Senator Bill Nelson (D-FL) sent a letter to Acting Secretary of the Army Robert Speer expressing strong concerns regarding the proposed exclusive license of a federally-funded Zika vaccine to Sanofi, stating that, “If the Army chooses to move forward with its plan to provide Sanofi Pasteur an exclusive license to sell this vaccine, it must first obtain assurances that the vaccine will be affordable to all who need it.” Senator Nelson is a senior member of the Committee on the Armed Services.

Continue Reading

Uncategorized

2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On June 5, 2017, KEI provided comments to the NIH/NCI, on a prospective grant of an exclusive license to PathoVax, relating to HPV vaccines. On July 10,… Continue Reading

2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors Useful for Treating Cancer

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 31, 2017, we sent the following comment to the NIH regarding the proposed exclusive license on certain patents for cancer treatment to GeneXion Oncology. May 31,… Continue Reading

KEI Statements on World Health Assembly Committee Passage of Cancer Resolution | May 30, 2017

For additional information, contact:

  • James Love (+41.76.413.6854 thru Wed., May 31, 2017, and +1.202.361.3040 thereafter, james.love@keionline.org)
  • Thiru Balasubramaniam (thiru@keionline.org, +41.76.508.0997)

The final text of the resolution (WHA70.12, Cancer prevention and control in the context of an integrated approach) can be found it here: http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_R12-en.pdf

Continue Reading

Uncategorized